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Introduction
Drug-induced liver injury (DILI) is one of the most frequent adverse reactions for the withdrawal of an approved drug from the market (Chen et al., 2013b) . Currently more than 50% of cases of acute liver failure in the United States are attributed to DILI (Lee et al., 2008) . Although DILI is complicated and difficult to predict because of its complex etiology, some simple rules can be followed to identify the drugs associated with the increased risk of liver injury. For example, the Rule-of-Two (RO2) based on combination of a daily dose (≥ 100 mg) and high lipophilicity (logP ≥ 3) has been proposed recently for the identification of drugs with increased risk of DILI (Chen et al., 2013a) . RO2 is an effective tool in preclinical application, and it will be particularly helpful for the drug screening. However, its use in the clinical setting is limited. This is largely due to the fact that RO2 is only focused on the drug properties, without taking into account the effects that the liver has on the drug, i.e. hepatic metabolism.
The highest concentration of drugs and metabolites after oral administration is usually exposed by the liver (Jaeschke et al., 2002) . Most hepatotoxic drugs are metabolized by the Cytochrome P450 (CYP) enzymes (FDA, 2009) , which are primarily involved in the generation of reactive metabolites (Williams et al., 2004) . The covalent binding of reactive metabolites to hepatic proteins has been considered as a key event for the occurrence of DILI in humans (Park et al., 2005; Walgren et al., 2005) . However, there are some exceptions. For example, ximelagatran, although not prone to generate reactive metabolites, has been withdrawn from the market because of DILI (Keisu and Andersson, DMD #56267 5 enzymes as either inhibitors or inducers. The exact role of these interaction modes in DILI has not been examined extensively.
It is known that dose-dependent liver toxicity is predictable, and the relationship between a daily dose of oral medications and DILI has also been observed (FDA, 2009) . It is found that most drugs which are required to carry black-box warnings or which have been withdrawn from the market due to DILI are prescribed at daily doses higher than 50 mg (Uetrecht, 2007) . However, DILI, which is not clearly dose-dependent, is unpredictable and hard to detect due to the differences in individual susceptibilities (FDA, 2009 ). In addition, polypharmacy and drug-drug interactions (DDIs) increase the risk of DILI (Stine et al., 2013) . Examining the large drug data sets may allow us to fill critical gaps in current knowledge on the role of hepatic metabolism in DILI, and thus to associate individual susceptibilities with DILI in the context of hepatic metabolism in clinical application.
CYP enzymes are involved in the metabolism of approximately 75% of the marketed drugs with a wide range of structural variations (Williams et al., 2004) . Often, several drugs are co-administered, which poses a challenge to a clinician who, without performing formal causality assessment, has to make a decision which drug should be stopped in case that clinical symptoms or signs of DILI are observed. The goal of our study was to find a simple rule applicable to the clinical settings, which will not only to avoid DILI risk when multiple drugs are treated to the patients, but also for personalized medicines to understand the individual susceptibility of DILI. We hypothesized that drugs which are CYP substrates, inhibitors and inducers may not have the same DMD #56267 likelihood of causing DILI and that a daily dose may not be equally important for these three groups of drugs.
Materials and Methods
Collection of data on CYP-mediated metabolism
The data on the metabolism mediated by CYP enzymes for the drugs from Liver Toxicity
(http://www.fda.gov/ScienceResearch/BioinformaticsTools), (Chen et al., 2011) developed by National 
Data analysis
The drugs in LTKB-BD are classified as Most-DILI, Less-DILI and No-DILI concern drugs (Chen et al., 2011) . We combined the Most-DILI and Less-DILI concern drugs into DILI positive drugs, while the remaining drugs were considered as DILI negatives. The drugs taken orally were classified according to their doses as drugs administered at high daily doses (≥ 100 mg) and drugs administered at low daily doses (< 100 mg). The daily dose ≥ 100 mg was considered as "a high daily dose" based on our previous findings that significantly higher proportion of medications administered orally at a daily dose ≥ 100 mg caused DILI (Chen et al., 2013a) . In addition, Stepan at al. also consider this dose as "a high daily dose" (Stepan et al., 2011) .
The conditional logistic regression was used to assess the association regarding the drugs which are CYP substrates, inhibitors or inducers and the drugs which are not, and whether the former has the higher likelihood of causing DILI compared to the latter. For each association, odds ratio (OR) with 95% confidence interval (CI) was reported.
Fisher's Exact Test was used to calculate a statistical significance of the associations.
Multivariate logistic regression was used to estimate the relationship between the This article has not been copyedited and formatted. The final version may differ from this version. 
The role of an individual CYP enzyme on DILI risk
Since the drug which is a substrate of CYP enzyme was closely associated with DILI risk, we further analyzed the association of the individual CYP enzyme with DILI risk. Most of these enzymes exhibited a high degree of inter-individual variations (Tanaka, 1999; Meibohm et al., 2002; Wolbold et al., 2003; Parkinson et al., 2004; Zhou et al., 2009 ), which could be relevant to the clinical application of DILI assessment. We found that drugs metabolized by CYP1A2, 2C8/9, and 3A5 may have the higher likelihood of causing DILI (Table 2) .
A combined assessment of the daily dose, lipophilicity and drug-CYP interaction modes in DILI
This article has not been copyedited and formatted. The final version may differ from this version. were not observed to be closely associated with DILI even when they were administered at a high daily dose. DILI caused by CYP substrates was both dose-and lipophilicityindependent.
Identifying significant drug-specific predictors for DILI
Multivariate logistic regression revealed that among multiple drug-specific variables (a high daily dose, high lipophilicity, the drug being a CYP substrate, an inhibitor, and an inducer), a high daily dose (OR (95% CI): 7.10 (3.36-15.0); p < 0.0001) and the drug being a substrate of CYP enzymes (OR (95% CI): 5.04 (2.34-10.9); p < 0.0001) were two significant predictors for DILI ( Each drug pair consists of a "clean" compound and a "toxic" compound. Both are similar in chemical structure and have identical primary target activity with exhibiting no liver toxicity in the preclinical study. When applying to humans, the "toxic" compound exhibits the more severe liver injury than the "clean" compound. Anxiolytic alpidem, antiparkinsonian tolcapone, and trovofloxacin which was used in the treatment of chronic granuloma inguinale, marked as "toxic" in three drug pairs were administered at high daily doses and at the same time they are CYP substrates. All non-steroidal antiinflammatory drugs (NSAIDs), i.e., benoxaprofen, ibuprofen, bromfenac, and diclofenac, were predicted to be hepatotoxic based on our two predictors (Table 5) .
A high daily dose and the drug being a CYP substrate in identifying drugs causing liver injury in clinical studies
A high daily dose and the drug being a substrate of CYP enzymes were also applied to identify drugs that might cause liver injury in 11 clinical cases from NIH LiverTox database (http://livertox.nlm.nih.gov/), where patients were treated with comedications.
In each case, causality assessment was confirmed by physicians or health care professionals. In these case studies, drugs that caused liver injury, i.e. cyclophosphamide, valproic acid, isoniazid, efavirenz, mercaptopurine, fluconazole, diclofenac, ketoconazole, fenofibrate, disulfiram, and ticlopidine, were identified by the two predictors (Table 6 ).
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Discussion
In this study, we analyzed how 254 orally administered drugs (i.e. CYP substrates, inhibitors or inducers) from LTKB-BD were associated with DILI. We discovered that drugs-substrates for CYP enzymes showed statistically significant, but dose-independent association with DILI; drugs-inhibitors for CYP enzymes would have the higher likelihood of causing DILI when they were administered at a high daily dose (≥ 100 mg).
On the contrary, drugs-inducers for CYP enzymes were not observed to be significantly associated with DILI. These findings will be helpful to identify the drug with the high likelihood of causing DILI in clinical settings.
We determined that a high daily dose and the drug being a substrate of CYP enzymes, which had the significantly higher likelihood of causing DILI, were two important predictors of DILI (Table 4 ). In addition, we also revealed that only the integration of a high daily dose and being a CYP substrate had a higher likelihood of causing DILI. A list of structural alerts associated with the formation of toxic reactive metabolites has been established (Kalgutkar et al., 2005) . However, the mere presence of a structural alert in a drug will not necessarily be associated with DILI (Stepan et al., 2011) . Some drugs with the same structural alerts may have different risk of DILI. For example, troglitazone, rosiglitazone, and pioglitazone contain the same thiazolidinedione scaffold, which is the structural alert to generate the toxic reactive metabolites. Troglitazone has been withdrawn because of DILI, while rosiglitazone and pioglitazone are now still in use.
Their daily dose may be a key difference, i.e., troglitazone (400 mg/day) versus rosiglizatone (6 mg/day) and pioglitazone (30 mg/day). On the contrary, the key difference to explain the different risk of DILI for ibuprofen (1200 mg/day) and ibufenac This article has not been copyedited and formatted. The final version may differ from this version. (2400 mg/day) is the formation of toxic reactive metabolite. Therefore, although high daily dose and being the CYP substrate are two independent factors associated with DILI, both of them should be considered to identify the DILI drugs.
The drug pairs have similar chemical structures and are usually expected to have similar efficacy and safety. The drugs marked as "toxic", which were withdrawn from the market in US or elsewhere due to DILI, i.e., alpidem, tolcapone, trovofloxacin, benoxaprofen, and bromfenac (Table 5) , were identified as positives by our two predictors of DILI.
Ibuprofen and diclofenac were also identified as DILI positive drugs, and their DILI potential was confirmed by the case reports of acute liver failure (ALF) (Helfgott et al., 1990; Banks et al., 1995; Javier Rodriguez-Gonzalez et al., 2002) . Because of the DILI potential of these two drugs, they are annotated as Less-DILI and Most-DILI concern drugs in LTKB, respectively (Chen et al., 2011) . Thus, our two predictors can identify the "toxic" compound in drug pair. Besides that, these two predictors of DILI could identify the drugs that caused DILI among multiple medications used by patients in clinical studies (Table 6 ). These results confirmed that two identified predictors of DILI (a high daily dose and the drug being a CYP substrate) could have useful clinical applications, particularly for a clinician in decision-making process when dealing with a patient suspected of having DILI. Nowadays, drug developers are encouraged to provide metabolism data on CYP enzymes for new drug applications (NDA) (FDA, 2012), which will facilitate a practical use of the identified two predictors of DILI in future.
It has been reported that almost all of the drugs known to be associated with DILI cause clinically significant DDIs (Li, 2002) . Many DDIs can be explained by the inhibition or induction of the expression of CYP enzymes in the liver (Tanaka, 1998 suggest that the clinically observed DILI may happen when the CYP inhibitors are administered at a high daily dose (Table 3) . Based on the mechanisms of enzyme inhibition, the CYP inhibitor needs to bind to the CYP enzymes and then decreases their activity. Therefore, the inhibitory effect is expected to be increased with the increasing dose of the inhibitor. Other authors also find that the inhibition of CYP enzymes is dosedependent (Lin et al., 2000; Hollenberg, 2002) . The inhibition of CYP enzymes may increase liver exposure of the parent drug, which has the potential to cause DILI. For example, clinically dose-dependent hepatotoxicity of fluconazole, which is a potent inhibitor of CYP2C19, and a moderate inhibitor of CYP2C9 and 3A, has been observed (Wells and Lever, 1992) . Phenytoin (300 mg/day) is an inhibitor of CYP2C9 with a narrow therapeutic index. It is also a substrate of CYP2C9. Therefore, the increased liver exposure of phenytoin by the inhibition of CYP2C9 might increase the risk of DILI.
Phenytoin has been considered as one of the most common drugs other than acetaminophen reported to cause ALF in the United States (Russo et al., 2004) , which confirmed our findings that the high dose of CYP inhibitors would have the higher likelihood of causing DILI. Inhibitory effects usually occur immediately; however, induction of CYP enzymes is usually both time-and dose-dependent (Markowitz et al., 2003) , which will lead to a delay before enzyme activity increases depending on duration of exposure and half-life of the inducer in the liver. Consequently, induction of hepatic CYP enzymes rarely leads to the altered metabolism and toxicity in the patient, which typically occurs only if the induction is very extensive (Mohutsky et al., 2010 Due to the differences in individual susceptibility to hepatotoxic drugs, our findings will be helpful for dose adjustment which is important in order to prevent DILI. For example, females are more susceptible to DILI than males (Russo et al., 2004) . That could be partly explained by twofold higher activity of CYP3A4 in the liver samples of females compared to the male samples (Wolbold et al., 2003) . CYP3A4 has the highest abundance in the human liver (~40%) and is the most prevalent enzyme involved in metabolism of DILI drugs (Li, 2002) . As indicated in this study, CYP2C would have the higher likelihood of metabolizing the DILI drugs. Therefore, Hispanics with about twice the activity of CYP2C over Caucasians and African Americans (Parkinson et al., 2004) , may have a higher risk to liver injury caused by drugs, such as NSAIDs, leflunomide, troglitazone and valproic acid, which are mainly metabolized by CYP2C (Kirchheiner and Brockmoller, 2005) . NSAIDs were reported as the most frequently used drugs causing DILI in Spain (Ibanez et al., 2002) .
This study has several limitations. Firstly, we do not have a confirmation which one among the CYP enzymes involved in the metabolism of the drugs participates in the formation of toxic reactive metabolites. Secondly, other enzymes rather than CYP isoforms can also mediate the generation of toxic reactive metabolites for some drugs, and their roles are not considered in this study. Thirdly, our results are based on in vitro data on CYP-mediated metabolism and their extrapolation to in vivo studies is uncertain.
Fourthly, the data on CYP-mediated metabolism for some drugs and the data on Since FDA is encouraging the industry to submit the metabolism data and safety data on drug metabolites for NDA, we can expect to summarize the more solid conclusions using the analysis we carried out in this study when those data are available in future. In addition, the authors should be encouraged by the journals to publish negative findings, as in that case it will be certain that drugs classified as "not the substrates of CYP enzymes" are not metabolized by particular CYP enzymes.
In summary, besides a high daily dose, our study indicates that the drug being a substrate of CYP enzymes is another important predictor of DILI. In addition, we have also found out that CYP inhibitors have a higher likelihood of causing DILI only when they are administered at a high daily dose, and CYP inducers are not observed to be closely The high daily dose and high lipophilicity were defined by the paper (Chen et al., 2013a) This article has not been copyedited and formatted. The final version may differ from this version. 
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